Roche Holding AG
ROG
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Stocks News & Analysis
stocks
3 cheap Wide Moat stocks in a divided industry
All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
stocks
10 global stocks for a recession
These undervalued stocks come from high-quality companies in defensive sectors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,571.40 | 40.30 | -0.47% |
| CAC 40 | 7,910.49 | 31.93 | -0.40% |
| DAX 40 | 24,122.40 | 86.29 | 0.36% |
| Dow JONES (US) | 41,860.44 | 816.80 | -1.91% |
| FTSE 100 | 8,782.48 | 3.98 | -0.05% |
| HKSE | 23,537.81 | 289.97 | -1.22% |
| NASDAQ | 18,872.64 | 270.07 | -1.41% |
| Nikkei 225 | 36,985.87 | 313.11 | -0.84% |
| NZX 50 Index | 12,662.25 | 40.85 | -0.32% |
| S&P 500 | 5,844.61 | 95.85 | -1.61% |
| S&P/ASX 200 | 8,348.70 | 38.10 | -0.45% |
| SSE Composite Index | 3,378.31 | 9.27 | -0.27% |